Audentes Therapeutics Inc (BOLD) Expected to Post Earnings of -$0.92 Per Share

Wall Street analysts expect that Audentes Therapeutics Inc (NASDAQ:BOLD) will report ($0.92) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Audentes Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.84) and the lowest estimate coming in at ($1.08). Audentes Therapeutics reported earnings of ($0.91) per share in the same quarter last year, which would indicate a negative year over year growth rate of 1.1%. The firm is scheduled to issue its next earnings results on Thursday, March 8th.

On average, analysts expect that Audentes Therapeutics will report full-year earnings of ($3.50) per share for the current fiscal year, with EPS estimates ranging from ($3.69) to ($3.42). For the next fiscal year, analysts expect that the business will report earnings of ($3.70) per share, with EPS estimates ranging from ($5.31) to ($3.20). Zacks’ EPS averages are an average based on a survey of analysts that follow Audentes Therapeutics.

BOLD has been the subject of a number of research reports. Leerink Swann reiterated an “outperform” rating and set a $29.00 price objective (up previously from $22.00) on shares of Audentes Therapeutics in a research report on Wednesday, November 15th. HC Wainwright set a $37.00 price objective on Audentes Therapeutics and gave the company a “buy” rating in a research report on Thursday, January 11th. Zacks Investment Research upgraded Audentes Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 9th. Mizuho initiated coverage on Audentes Therapeutics in a research report on Monday. They set a “neutral” rating and a $26.00 price objective for the company. Finally, BidaskClub cut Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Audentes Therapeutics has a consensus rating of “Buy” and an average target price of $34.00.

In other Audentes Therapeutics news, Director Louis G. Lange sold 18,000 shares of the company’s stock in a transaction dated Friday, December 22nd. The stock was sold at an average price of $30.88, for a total value of $555,840.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Suyash Prasad sold 8,000 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $28.53, for a total value of $228,240.00. The disclosure for this sale can be found here. Corporate insiders own 47.30% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of BOLD. Vanguard Group Inc. increased its position in Audentes Therapeutics by 130.3% in the second quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock worth $12,978,000 after buying an additional 383,837 shares in the last quarter. Farallon Capital Management LLC purchased a new stake in Audentes Therapeutics in the fourth quarter worth about $9,989,000. Citadel Advisors LLC increased its position in Audentes Therapeutics by 206.2% in the fourth quarter. Citadel Advisors LLC now owns 339,588 shares of the biotechnology company’s stock worth $10,612,000 after buying an additional 228,667 shares in the last quarter. Artal Group S.A. purchased a new stake in shares of Audentes Therapeutics during the third quarter worth about $5,602,000. Finally, BlackRock Inc. grew its position in shares of Audentes Therapeutics by 13.2% during the fourth quarter. BlackRock Inc. now owns 1,358,498 shares of the biotechnology company’s stock worth $42,452,000 after purchasing an additional 158,576 shares in the last quarter. Institutional investors and hedge funds own 64.94% of the company’s stock.

Audentes Therapeutics (NASDAQ BOLD) traded up $0.81 during trading on Thursday, reaching $32.82. The company had a trading volume of 195,000 shares, compared to its average volume of 533,067. The stock has a market capitalization of $1,163.45, a PE ratio of -9.40 and a beta of 0.41. Audentes Therapeutics has a 12 month low of $13.90 and a 12 month high of $41.80.

TRADEMARK VIOLATION NOTICE: “Audentes Therapeutics Inc (BOLD) Expected to Post Earnings of -$0.92 Per Share” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/02/15/audentes-therapeutics-inc-bold-expected-to-post-earnings-of-0-92-per-share.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Get a free copy of the Zacks research report on Audentes Therapeutics (BOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply